Skip to Main Content

Advertisement

Skip Nav Destination

FDA Warns Bayer After Routine Inspection of Facilities

December 30, 2021

The U.S. Food and Drug Administration (FDA) sent a warning letter to Bayer about drug manufacturing practices at its German headquarters. The FDA's complaints were triggered by a routine inspection in January of this year.

In a statement, the company said the regulatory agency has no evidence of risk to patient safety. As a result of this inspection and the time to complete the necessary corrective actions, Bayer expects temporary supply limitations on some of its products, including Adalat, Aspirin Cardio, Avelox, and Levitra.

Source: Reuters, February 14, 2018.

Advertisement

Connect with us:

CURRENT ISSUE
September 2022

Advertisement

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement